UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation
Journal of Extracellular Vesicles · 2024
DOI: 10.1002/jev2.12491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2024. Verfasst von Shaoqin Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Extracellular Vesicles, Biomarkers, Tumor, Prostate-Specific Antigen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
In the quest for efficient tumor diagnosis via liquid biopsy, extracellular vesicles (EVs) have shown promise as a source of potential biomarkers. This study addresses the gap in biomarker efficacy for predicting clinically significant prostate cancer (csPCa) between the Western and Chinese populations. We developed a urinary extracellular vesicles‐based prostate score (EPS) model, utilizing the EXODUS technique for EV isolation from 598 patients and incorporating gene expressions of FOXA1, PCA3, and KLK3. Our findings reveal that the EPS model surpasses prostate‐specific antigen (PSA) testing in diagnostic accuracy within a training cohort of 234 patients, achieving an area under the curve (AUC) of 0.730 compared to 0.659 for PSA ( p = 0.018). Similarly, in a validation cohort of 101 men, the EPS model achieved an AUC of 0.749, which was significantly better than PSA's 0.577 ( p < 0.001). Our model has demonstrated a potential reduction in unnecessary prostate biopsies by 26%, with only a 3% miss rate for csPCa cases, indicating its effectiveness in the Chinese population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
- Shenzhen Huixin Lifetechnologies Co., Ltd., Longhua, Shenzhen, Guangdong, China.
- Department of Clinical Laboratory, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Urology, Changhai Hospital, Shanghai, China.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Fei Liu
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
Zitieren
APA
Jiang, S., Lu, F., Chen, J., Jiao, Y., Qiu, Q., Nian, X., Qu, M., Wang, Y., Li, M., Liu, F., & Gao, X. (2024). UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12491
Vancouver
Jiang S, Lu F, Chen J, Jiao Y, Qiu Q, Nian X, et al. UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.12491
BibTeX
@article{Jiang2024,
author = {Jiang, Shaoqin and Lu, Feiting and Chen, Jiadi and Jiao, Yingzhen and Qiu, Qingqing and Nian, Xinwen and Qu, Min and Wang, Yan and Li, Mengqiang and Liu, Fei and Gao, Xu},
title = {UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation},
journal = {Journal of Extracellular Vesicles},
year = {2024},
doi = {10.1002/jev2.12491}
}
EUVIMED